HM2017-02 A randomized, double-blind, placebo-controlled phase 2 study of vadastuximab talirine (SGNCD33A) in combination with cytarabine and daunorubicin (7+3) induction chemotherapy for newlydiagnosed acute myeloid leukemia patients (SGN33A-006)
|Effective start/end date||1/1/17 → 10/1/17|
- Seattle Genetics, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.